|
|
|
| Change of serum gammaglutamyltransferase in newlydiagnosed type 2 diabetes treated with shortterm continuous subcutaneous insulin infusion |
| DONG Si-Jing, Ye Jing-Jing, Zhang Cai-Li, et al |
| Department of Endocrinology, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001, China |
|
|
|
|
Abstract Objective: To investigate the effects of shortterm continuous subcutaneous insulin infusion (CSII) on serum gammaglutamyltransferase (GGT) levels in patients with newlydiagnosed type 2 diabetes mellitus, and to study the association between insulin resistance and GGT. Methods: Thirtytwo patients with newlydiagnosed type 2 diabetes mellitus were treated with CSII for 2 weeks. Oral glucose tolerance test and insulin releasing test were performed before and after intensive insulin therapy, meanwhile, blood lipid, serum GGT and other items were measured. Results: ① Two weeks of CSII treatment in type 2 diabetic patients resulted in significant reduction in fasting serum insulin［(11.60±2.89） vs(6.82±1.01)mmol/L, P<0.01］, postprandial serum insulin［(22.52±4.57）vs(13.81±3.10)mmol/L, P<0.01］ and homeostasis model assessment for insulin resistance(HOMAIR)\[2.20(1.45~3.07) vs 1.37(0.89~1.90), P<0.01\]. ② After CSII treatment for 2 weeks, the level of serum GGT was decreased significantly \[24.00(18.00~35.00) vs 18.00(16.00~27.00) U/L, P=0.005\]. ③ Serum GGT level was positively correlated with HOMAIR（r=0.418，P<0.05）. Meanwhile, changes in serum GGT levels were positively correlated with changes in HOMAIR（r=0.433，P<0.05）. ④ The multiple regression analysis showed that the HOMAIR were independent related factors in the influence of the serum GGT levels．Conclusion: In type 2 diabetic patients, elevated serum GGT levels were significantly decreased after CSII treatment. It might indicate that serum GGT plays an important role in the development of insulin resistance．
|
|
Received: 08 August 2012
|
|
|
|
|
|
|
2012, Vol. 22 
